NCT06992336View on ClinicalTrials.gov

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

April 10, 2031

Study Completion Date

January 1, 2036

Conditions
Breast Cancer
Interventions
DRUG

Anlotinib ,

Anlotinib 8mg qd PO，357days

DRUG

Benmelstobart

Benmelstobart 200mg i.v. Q3W

DRUG

Capecitabine

Capecitabine 1000 or 1250 mg/m2 BID day1-14

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER